New therapeutic targets and therapeutic agents for trauma-induced heterotopic ossification in FOP patients.
D35LNPs stimulate TLR9 and significantly induce the release of IFN-α from plasmacytoid dendritic cells, thereby strongly enhancing systemic immunity
siRNAs containing innovative artificial nucleic acids selectively suppress mRNAs containing abnormally expanded CAG repeats
Improved S-TuD (Synthetic Tough Decoy) RNA nucleic acid that inhibits miR-200 family, which is highly expressed in mammary cancer, colon cancer, endometrial cancer, ovarian cancer, etc.
Using vesicles derived from the cell membrane of target bacteria allows for highly species-specific treatment
Identification of prostaglandin receptors involved in the pathogenesis of endometriosis. [Collaborative Research Proposal]
RNA-binding molecules, such as antisense oligonucleotides and small molecules, facilitate back-splicing progression and augment circular RNA
Therapeutic target molecules and antisense oligonucleic acid (ASO) therapeutic agents for autosomal dominant polycystic kidney disease (ADPKD).
Nucleic acid drug that suppresses aggregate formation through regulation of α-synuclein (αSyn) gene expression.
ASO-4733: Optimized Anti-SYT13 antisense oligonucleotides
Newly designed KK-(EK)4-lipid having near neutral charge enhances intracellular translocation of drug carrier
Specific miRNAs as active ingredients for the treatment and prevention of cellular senescence and bisphosphonate-related osteonecrosis of the jaw (BRONJ)
Molecular targeted drugs targeting the NIK associated with the differentiation factor from hepatocytes to cholangiocarcinoma
Prediction of the efficacy of cancer immunotherapy using the tumor-targeting activity of T cells in peripheral blood.
Overcoming the challenges of mRNA medicine by improving translation efficiency
-Two independent antisense oligonucleotides (ASOs) targeting GREB1 and Arl4c gene-
About Bionauts.jp
